Yes, startup is accurate. Generally biotech startups place bets on a few potential drugs or therapies that yield huge payoffs...or nothing. Seven Years to get those drugs or therapies to a place where they can be monitized is reasonable.We are 5 years into that timeline with HemaXellerate. If it's too risky for most investors that's OK. I believe we're close to ODD and a SP over a dollar. That crazy to many....until it comes true.
Market Data 
Markets 
AI
